Celestial Therapeutics Joins the Mayo Clinic Innovation Exchange
Celestial Therapeutics Inc. (“Celestial”) is pleased to announce that it has been accepted into the Mayo Clinic Innovation Exchange (“MCIE”).
Through acceptance into this exchange, Celestial will be able to leverage the following MCIE resources to advance its lead dual modal antiviral/anti-inflammatory therapeutic, CT-02 for the treatment of viral myocarditis into human clinical trials and to support Celestial’s business plan:
Opportunities to interact and collaborate with world-class clinicians and scientific personnel who are members of the Mayo Clinic community;
Availability of resources and support from MCIE affiliate partners, including leading providers of education, legal, accounting, marketing, business consulting, venture capitalists and other key operational partners.
Inclusion in the MCIE is a significant achievement for Celestial. This development will enable Celestial to leverage Mayo Clinic’s vast network, expertise and support within several specialties to accelerate Celestial’s near-term growth in measurable and meaningful ways and represents a major milestone in the growth of the company for advancing its lead candidates to the clinic.
About Celestial Therapeutics
Celestial is a California based startup biotechnology company developing a first in class of a new class of non-steroidal anti-inflammatories, a new class of dual-modal anti-infective and anti-inflammatory drugs and novel mRNA vaccines & therapeutics for conditions which currently lack safe and effective treatments. Celestial’s mission is to effectively treat respiratory infections & inflammatory conditions, cancers, prevent pandemics, save lives, reduce healthcare costs and address unmet medical needs for millions of patients worldwide. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies. Celestial’s lead therapeutic candidate, CT-02, is being developed as a first-ever broad spectrum dual-modal antiviral & anti-inflammatory inhalation therapeutic for treating lung infections due to Respiratory Syncytial Virus (RSV). Celestial’s new mRNA vaccine, CT-03 is being developed for the prevention of viral infections arising from Chikungunya leveraging its novel and proprietary next generation Stellar-mRNA platform. Celestial’s anti-inflammatory therapeutics have the potential to provide safer and more effective alternative treatments to the existing steroidal and non-steroidal anti-inflammatories currently on the market. The Celestial team consists of industry veterans and prominent academicians with a proven track record.
To learn more, visit https://www.celestialtherapeutics.com
About the Mayo Clinic Innovation Exchange
The Mayo Clinic Innovation Exchange is a comprehensive platform designed to accelerate healthcare innovation by connecting innovators, partners, and industry experts. Its mission is to share knowledge globally and foster collaborations that bring breakthroughs to market more efficiently. Members gain exclusive access to Mayo Clinic stakeholders, strategic industry connections, and essential support to scale innovations. The platform offers curated events that focus on critical topics such as regulatory pathways, funding strategies, and market access, empowering innovators to make a lasting impact on healthcare.